Drug Profile

APG 2449

Alternative Names: APG-2449

Latest Information Update: 14 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ascentage Pharma
Class Antineoplastics; Small molecules
Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion kinase 1 inhibitors; ROS1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Ovarian cancer; Solid tumours
Preclinical Acute myeloid leukaemia; Small cell lung cancer

Most Recent Events

14 May 2025 Ascentage Pharma plans a clinical trial for Small cell lung cancer
28 Apr 2025 Preclinical trials in Small cell lung cancer (Combination therapy) in China (PO) prior to April 2025
28 Apr 2025 Pharmacodynamics data from a preclinical study in Small cell lung cancer released by Ascentage Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com